|
|
||||||||
Published online before print March 12, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* The Cardiovascular Institute, Department of Medicine, The Mount Sinai School of Medicine, New York, New York;
The Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts;
Departments of Pathology and Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York; and
Gladstone Institute of Cardiovascular Disease and the Cardiovascular Research Institute, Department of Medicine, University of California, San Francisco
1 Correspondence: Box 1030, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. E-mail: alison.schecter{at}mssm.edu
Monocyte chemoattractant protein-1 (MCP-1, CCL2) is a mediator of inflammation that has been implicated in the pathogenesis of a wide variety of human diseases. CCR2, a heterotrimeric G-coupled receptor, is the only known receptor that functions at physiologic concentrations of MCP-1. Despite the importance of CCR2 in mediating MCP-1 responses, several recent studies have suggested that there may be another functional MCP-1 receptor. Using arterial smooth muscle cells (SMC) from CCR2/ mice, we demonstrate that MCP-1 induces tissue-factor activity at physiologic concentrations. The induction of tissue factor by MCP-1 is blocked by pertussis toxin and 1,2-bis(O-aminophenyl-ethane-ethan)-N,N,N',N'-tetraacetic acid-acetoxymethyl ester, suggesting that signal transduction through the alternative receptor is G
i-coupled and dependent on mobilization of intracellular Ca2+. MCP-1 induces a time- and concentration-dependent phosphorylation of the mitogen-activated protein kinases p42/44. The induction of tissue factor activity by MCP-1 is blocked by PD98059, an inhibitor of p42/44 activation, but not by SB203580, a selective p38 inhibitor. These data establish that SMC possess an alternative MCP-1 receptor that signals at concentrations of MCP-1 that are similar to those that activate CCR2. This alternative receptor may be important in mediating some of the effects of MCP-1 in atherosclerotic arteries and in other inflammatory processes.
Key Words: chemokine tissue factor vascular smooth muscle receptors genetically altered mice kinases
This article has been cited by other articles:
![]() |
L. Yahiaoui, D. Gvozdic, G. Danialou, M. Mack, and B. J. Petrof CC family chemokines directly regulate myoblast responses to skeletal muscle injury J. Physiol., August 15, 2008; 586(16): 3991 - 4004. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2563 - 2568. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Shireman, V. Contreras-Shannon, O. Ochoa, B. P. Karia, J. E. Michalek, and L. M. McManus MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration J. Leukoc. Biol., March 1, 2007; 81(3): 775 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Wareing, A. Lyon, C. Inglis, F. Giannoni, I. Charo, and S. R. Sarawar Chemokine regulation of the inflammatory response to a low-dose influenza infection in CCR2-/- mice J. Leukoc. Biol., March 1, 2007; 81(3): 793 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Kruglov, R. A. Nathanson, T. Nguyen, and J. A. Dranoff Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G765 - G771. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kodali, M. Hajjou, A. B. Berman, M. B. Bansal, S. Zhang, J. J. Pan, and A. D. Schecter Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells Cardiovasc Res, February 15, 2006; 69(3): 706 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Marra Renaming cytokines: MCP-1, Major Chemokine in Pancreatitis Gut, December 1, 2005; 54(12): 1679 - 1681. [Full Text] [PDF] |
||||
![]() |
G. P. de Lema, H. Maier, T. J. Franz, M. Escribese, S. Chilla, S. Segerer, N. Camarasa, H. Schmid, B. Banas, S. Kalaydjiev, et al. Chemokine Receptor Ccr2 Deficiency Reduces Renal Disease and Prolongs Survival in MRL/lpr Lupus-Prone Mice J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3592 - 3601. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Raines and N. Ferri Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J. Lipid Res., June 1, 2005; 46(6): 1081 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Charo and M. B. Taubman Chemokines in the Pathogenesis of Vascular Disease Circ. Res., October 29, 2004; 95(9): 858 - 866. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |